ALX Oncology Holdings ALXO 深 滬
已收盤 06-18 16:00:00 美东时间
1.53
+0.080
+5.52%
華盛通- 最 高1.545
- 今 開1.44
- 成交量 504.90万股
- 最 低 1.405
- 昨 收 1.45
- 總市值 2.06亿
- 52周最高 2.66
- 市盈率 靜 --
- 換手率 3.75%
- 52周最低 0.4102
- 委 比 -21.63%
- 總股本 1.35亿
- 歷史最高 117.45
- 量 比 3.58
- 振 幅 9.66%
- 歷史最低 0.404
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
ALX Oncology Holdings Inc. announced that its leadership will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 5:30 PM ET. The webcast can be accessed via their website or the provided link. ALX Oncology focuses on developing innovative cancer therapies, with its lead candidate, evorpacept, and ALX2004, an EGFR-targeted antibody-drug conjugate, currently in clinical trials.
06-01 12:00
ALX Oncology Holdings Q1 Adj. EPS $(0.15) Beats $(0.22) Estimate
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 68.75 percent increase over losses of $(0.48) per share
05-08 20:02
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology reported positive data from its Phase 1b/2 trial of evorpacept combined with zanidatamab in HER2-positive breast cancer patients, showing durable responses, particularly in those with high CD47 expression. The company also highlighted progress in its ASPEN-09-Breast Phase 2 trial and ALX2004 Phase 1 trial. Additionally, ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer, strengthening its leadership team. T...
05-08 12:00
ALX Oncology To Present New Data From Phase 1b/2 Clinical Trial Evaluating Investigational CD47-Inhibitor Evorpacept In Combination With Jazz's Zanidatamab In HER2-Positive mBC At ESMO Breast Cancer 2026 Congress
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 -SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a
04-30 20:06
ALX Oncology announces annual shareholder meeting webcast
ALX Oncology announces annual shareholder meeting webcast ALX Oncology annual shareholder meeting set for June 10, 2026 in virtual format. Shareholders will vote on election of three Class III directors to serve through 2029. Ballot also includes advisory vote on named executive officer compensation
04-23 12:50
ALX Oncology publishes 2025 annual report
ALX Oncology publishes 2025 annual report ALX Oncology annual report for fiscal 2025 highlighted continued focus on two clinical-stage programs, CD47 blocker evorpacept, EGFR-targeted ADC ALX2004. Evorpacept strategy shifted toward combinations with Fc-active anti-cancer antibodies to drive antibody
04-23 10:55
ALX Oncology Appoints Jeff Knight to Lead Development
ALX Oncology Holdings ( ($ALXO) ) has shared an update. On April 13, 2026, ALX ...
04-13 20:58
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Wells Fargo Initiates Coverage On ALX Oncology Holdings with Overweight Rating, Announces Price Target of $5
Wells Fargo analyst Derek Archila initiates coverage on ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight rating and announces Price Target of $5.
03-19 21:02
